We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+13.76%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$3.69B
AUM Growth
+$332M
Cap. Flow
+$42.5M
Cap. Flow %
1.15%
Top 10 Hldgs %
69.25%
Holding
31
New
4
Increased
15
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
ALDR
Alder Biopharmaceuticals
ALDR
+$42M
2
JUNO
Juno Therapeutics, Inc.
JUNO
+$23.9M
3
KITE
Kite Pharma, Inc.
KITE
+$20M
4
CEMP
Cempra, Inc.
CEMP
+$19.2M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$18.1M

Top Sells

Rank Stock Value
1
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$100M
2
IMGN
Immunogen Inc
IMGN
+$25.4M
3
GILD icon
Gilead Sciences
GILD
+$16.4M
4
INVA icon
Innoviva
INVA
+$8.59M
5
HALO icon
Halozyme
HALO
+$6.08M

Sector Composition

Rank Sector Weight
1 Healthcare 92.58%
2 Miscellaneous 7.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KITE
26
DELISTED
Kite Pharma, Inc.
KITE
$21.3M 0.58%
+350,000
New +$20M
ACHN
27
DELISTED
Achillion Pharmaceuticals
ACHN
$11.3M 0.31%
1,279,340
– –
INVA icon
28
Innoviva
INVA
$1.51B
$5.99M 0.16%
331,594
-500,000
-60% -$8.59M
TBPH icon
29
Theravance Biopharma
TBPH
$885M
$4.68M 0.13%
+359,190
New +$5.57M
IMGN
30
DELISTED
Immunogen Inc
IMGN
– –
-2,840,816
Closed -$25.4M
GEVA
31
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
– –
-1,025,476
Closed -$100M
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 9.56% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 0.35% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q2 2015 Portfolio in Review

As of Q2 2015, BB Biotech held 31 positions worth $3.69B, up 9.9% from $3.36B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

BB Biotech's Q2 2015 filing shows 4 new, 15 increased, 5 reduced and 2 closed positions. Its largest new stake was Alder Biopharmaceuticals: 1,155,150 shares worth $61.2M. The largest sale was SYNAGEVA BIOPHARMA CORP COM STK (DE), an estimated $100M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 89% a quarter earlier, followed by Miscellaneous.

  • BB Biotech's largest Q2 2015 buy was Alder Biopharmaceuticals: 1,155,150 shares worth $61.2M.
  • BB Biotech added most to Cempra, Inc. in Q2 2015, an estimated $19.2M increase.
  • BB Biotech's biggest Q2 2015 reduction was Gilead Sciences, cutting an estimated $16.4M.
  • BB Biotech fully exited SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2015, selling an estimated $100M.
  • BB Biotech's ten largest holdings make up 69% of its $3.69B portfolio in Q2 2015.
  • BB Biotech opened 4 new positions and closed 2 in Q2 2015.
  • BB Biotech's portfolio value rose 9.9% quarter-over-quarter to $3.69B.

Based on BB Biotech's 13F filing for Q2 2015, filed 12 Aug 2015.